OTC:BNOEF

Bionomics Limited Announces Pricing of Initial Public Offering in the United States

ADELAIDE, Australia, Dec. 16, 2021 /PRNewswire/ -- Bionomics Limited (Bionomics orCompany), a clinical-stage biopharmaceutical company, today announced the pricing of its initial public offering inthe United States (the Offering) of 1,622,000 American Depositary Shares (ADSs), each representing 1...

2021-12-16 19:00 2449

U.S. FDA Grants Bionomics Fast Track Designation to BNC210 for the Acute Treatment of Social Anxiety Disorder and Other Anxiety Related Disorders

ADELAIDE, Australia, Dec. 1, 2021 /PRNewswire/ -- Bionomics Limited (ASX:BNO, OTCQB:BNOEF) (Bionomics or Company), a clinical-stage biopharmaceutical company, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the BNC210 development progr...

2021-12-01 19:00 2456

Bionomics Files Registration Statement for Proposed Initial Public Offering in the United States

ADELAIDE, Australia, Nov. 23, 2021 /PRNewswire/ -- Bionomics Limited (ASX:BNO, OTCQB:BNOEF) (Bionomics or Company), a clinical-stage biopharmaceutical company, today announced the public filing of a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the "SEC") in...

2021-11-23 19:37 2716

Bionomics Receives FDA Clearance of IND for Evaluation of BNC210 in a Phase 2 Social Anxiety Disorder PREVAIL Study

* U.S. FDA clearance of IND for BNC210 evaluation as an acute treatment for patients with Social Anxiety Disorder in a Phase 2 clinical trial, the PREVAIL Study * The PREVAIL Study remains on target to initiate by end of 2021 and is expected to read out topline data by end of 2022 ADELAIDE, A...

2021-11-01 18:00 2217

Bionomics Announces Plans to Conduct U.S. Initial Public Offering

ADELAIDE, Australia, Aug. 2, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB: BNOEF), (Bionomics) a global, clinical stage biopharmaceutical company, is pleased to announce that it plans to conduct a registered initial public offering of American Depositary Shares (ADSs) in the United ...

2021-08-02 18:00 13879

Bionomics Initiates Phase 2b ATTUNE Study of BNC210 in PTSD

ADELAIDE, Australia, July 6, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB:BNOEF) (Bionomics or Company), a global, clinical stage biopharmaceutical company, is pleased to announce that it has initiated a Phase2b trial (the ATTUNE Study) to evaluate the tablet formulation of BNC210 in p...

2021-07-06 18:00 17008

Bionomics Successfully Completes A$22.9 million Equity Raise

ADELAIDE, Australia, April 9, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB:BNOEF) (Bionomics) has completed its 1 for 6 pro rata non–renounceable entitlement offer that was announced on8 March 2021 (Entitlement Offer) and concurrent placement that was announced on17 March 2021 (Concurr...

2021-04-09 18:00 6939

Positive BNC210 7-Day Dosing Pharmacokinetic Study Exceeds Blood Exposure Projected for Phase 2b PTSD Trial

* BNC210 novel oral tablet formulation (900 mg given twice daily) exceeds blood exposure projected for upcoming Phase2b PTSD trial * BNC210 Phase 2b PTSD trial on target for start in mid-2021 with final dose selected ADELAIDE, Australia, Feb. 22, 2021 /PRNewswire/ -- Bionomics Limited (ASX: B...

2021-02-22 19:00 3163

Joint feasibility assessment of Bionomics' BNC210 and EmpathBio's MDMA derivative EMP-01 treatment regimen for PTSD

ADELAIDE, Australia, Feb. 17, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB: BNOEF,Germany: AU000000BNO5) (Bionomics) today announced that it has entered into a Memorandum of Understanding with EmpathBio Inc (EmpathBio), a wholly owned subsidiary ofGermany-based CNS clinical development...

2021-02-17 19:00 5923

$16 Million Capital Raise to Progress Bionomics BNC210 PTSD Trial

* Commitments received for a placement of A$15,991,634 at A$0.145 per share * Significant participation from North American and European institutional and sophisticated investors * This capital raising enables proceeding with the Phase 2b PTSD trial in mid-2021 as planned and sees the Compan...

2021-02-10 19:00 8085